American International Group’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-23,712
| Closed | -$88K | – | 3041 |
|
|
2017
Q4 | $88K | Buy |
23,712
+731
| +3% | +$2.99K | ﹤0.01% | 2787 |
|
|
2017
Q3 | $94K | Buy |
22,981
+1,718
| +8% | +$6.57K | ﹤0.01% | 2688 |
|
|
2017
Q2 | $79K | Buy |
+21,263
| New | +$84.4K | ﹤0.01% | 2864 |
|
|
2016
Q2 | – | Sell |
-9,986
| Closed | -$76K | – | 4873 |
|
|
2016
Q1 | $76K | Hold |
9,986
| – | – | ﹤0.01% | 3620 |
|
|
2015
Q4 | $133K | Sell |
9,986
-18
| -0.2% | -$310 | ﹤0.01% | 3238 |
|
|
2015
Q3 | $164K | Buy |
10,004
+12
| +0.1% | +$246 | ﹤0.01% | 3015 |
|
|
2015
Q2 | $224K | Buy |
9,992
+1,530
| +18% | +$24.2K | ﹤0.01% | 2897 |
|
|
2015
Q1 | $82.8K | Hold |
8,462
| – | – | ﹤0.01% | 3707 |
|
|
2014
Q4 | $96.5K | Buy |
8,462
+754
| +10% | +$8.18K | ﹤0.01% | 3618 |
|
|
2014
Q3 | $88.8K | Sell |
7,708
-5
| -0.1% | -$76 | ﹤0.01% | 3643 |
|
|
2014
Q2 | $150K | Buy |
+7,713
| New | +$136K | ﹤0.01% | 3250 |
|
|
2013
Q3 | – | Sell |
-6,558
| Closed | -$61.4K | – | 4811 |
|
|
2013
Q2 | $61.4K | Buy |
+6,558
| New | +$84.2K | ﹤0.01% | 3467 |
|
American International Group's CASC Position: Q1 2018 in Review
American International Group sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 23,712 shares — an estimated $88K sold.
American International Group first reported a position in CASC in Q2 2013 and held it in 12 quarters. The position peaked at $224K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- American International Group reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- American International Group sold 23,712 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $88K.
- American International Group first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 12 quarters.
- American International Group's Cascadian Therapeutics, Inc. position peaked at $224K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on American International Group's 13F filing for Q1 2018, filed 7 May 2018.